In the complex tapestry of leadership, awareness isn’t just a desirable trait; it’s the bedrock upon which success is built. It’s the lens through which leaders perceive, interpret, and navigate the ever-shifting landscape of their organizations and industries. Without it,…
BUSINESS
Daiichi Eyes 9 New Indications for 2 Lead ADCs, Tripling Patient Number by 2026
Daiichi Sankyo predicts its two lead antibody drug conjugates (ADCs) Enhertu (trastuzumab deruxtecan) and Datroway (datopotamab deruxtecan) could potentially gain a total of nine indications and triple the number of treated patients by 2026, the company said at its oncology…
To read the full story
BUSINESS
- Alfresa, K Pharma Tie Up on iPS Cell-Derived Therapy KP8011
November 7, 2025
- Fujifilm to Launch ADC-Focused CDMO Services First in Japan
November 7, 2025
- Otsuka Launches Global PIII for Drug-Resistant Tuberculosis Therapy
November 7, 2025
- Novo Nordisk Taps Keisuke Kotani as New Japan Chief
November 7, 2025
- Leqembi Sales Soar 153% in H1 FY2025; Eisai Pins Hopes on Self-Injector, Blood Tests
November 6, 2025
Japan’s Ministry of Health, Labor and Welfare (MHLW) proposed a full review of the so-called “G1/G2” rule — a framework…
Japan’s drug wholesalers are facing mounting financial pressure as rising logistics and procurement costs deepen losses on product distribution, even…
Japan’s Central Social Insurance Medical Council (Chuikyo) on October 15 approved the reimbursement listing of five new medicines, with the…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…